title: Effect of progesterone administration on prognosis of patients with diffuse axonal injury due to severe head trauma.
abstract: OBJECTIVE
  Severe traumatic brain injury (TBI) has a major role in mortality rate among the other types of trauma. The aim of this clinical study was to assess the effect of progesterone on the improvement of neurologic outcome in patients with acute severe TBI.
  
  
  METHODS
  A total of 76 patients who had arrived within 8h of injury with a Glasgow Coma Score≤8 were enrolled in the study. In a randomized style 38 received progesterone (1mg/kg per 12h for 5 days) and 38 did not.
  
  
  RESULTS
  There was a better recovery rate and GOS score for the patients who were given progesterone than for those in the control group in a 3-months follow-up period (50% vs. 21%); subgroup analysis showed a significant difference in the percentage of favorable outcome between the two groups with GCS of 5-8 (p=0.03).
  
  
  CONCLUSIONS
  The use of progesterone may significantly improve neurologic outcome of patients suffering severe TBI up to 3 months after injury, especially those with 5≤GCS≤8, providing a potential benefit to the treatment of acute severe TBI patients. Considering this drug had no significant side effects, so progesterone could be used in patients with severe TBI as a neuro-protective drug.
authors.affiliation: Department of Neurosurgery, Imam Reza Teaching Hospital, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Moslem
authors.initials: M
authors.lastname: Shakeri
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Boustani
authors.forename: Neda
authors.initials: N
authors.lastname: Pak
authors.forename: Farid
authors.initials: F
authors.lastname: Panahi
authors.forename: Firouz
authors.initials: F
authors.lastname: Salehpour
authors.forename: Iraj
authors.initials: I
authors.lastname: Lotfinia
authors.forename: Ali
authors.initials: A
authors.lastname: Meshkini
authors.forename: Shadi
authors.initials: S
authors.lastname: Daghighi
authors.forename: Payman
authors.initials: P
authors.lastname: vahedi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Khani
authors.forename: Dariush
authors.initials: D
authors.lastname: Taghiloo
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001930:Brain Injuries / Q000188:drug therapy; D006259:Craniocerebral Trauma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D020833:Diffuse Axonal Injury / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015600:Glasgow Coma Scale; D023261:Glasgow Outcome Scale; D006801:Humans; D007492:Iran / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018458:Persistent Vegetative State / Q000453:epidemiology; D011374:Progesterone / Q000627:therapeutic use*; D011379:Prognosis; D016037:Single-Blind Method; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D018696:Neuroprotective Agents; D011374:Progesterone
keywords: Diffuse axonal injury; Glasgow coma scale; Neuro-protective agent; Progesterone; Traumatic brain injury